Viking Therapeutics’ VK2735 Shows Promising Results for Obesity Treatment
Viking Therapeutics Inc. (VKTX) is making headlines with promising clinical data from its VK2735 obesity program, presented at ObesityWeek 2024. The company is exploring both subcutaneous and oral formulations of VK2735, aiming to offer a versatile treatment option for individuals battling obesity.
Encouraging Results from Phase 1 and Phase 2 Trials
Data from the Phase 1 multiple ascending dose (MAD) trial showcased encouraging results for the oral tablet formulation of VK2735. After 28 days of daily dosing, participants receiving VK2735 experienced dose-dependent reductions in mean body weight, reaching up to 8.2%. Compared to placebo, these reductions ranged up to 6.8%. Notably, the weight loss effects persisted even four weeks after the last VK2735 dose was administered.
The Phase 2 VENTURE trial, featuring weekly doses of VK2735, also yielded significant findings. Patients achieved statistically significant reductions in mean body weight after 13 weeks, with some experiencing a remarkable 14.7% decrease from baseline. These weight loss improvements were progressive throughout the study, with no plateau observed. Importantly, up to 88% of participants in VK2735 treatment groups achieved at least a 10% weight loss, compared to just 4% in the placebo group.
Beyond Weight Loss: Potential Metabolic Benefits
The VENTURE trial also revealed promising metabolic benefits. An exploratory analysis showed that VK2735 increased the odds of patients with prediabetic status transitioning to normal glycemic levels. Additionally, the proportion of patients with normal glycemic status at baseline who transitioned to prediabetic status was significantly lower in the VK2735 group compared to the placebo group.
Safety and Tolerability Profile
VK2735 demonstrated a favorable safety and tolerability profile following 28 days of once-daily dosing at doses up to 100 mg.
Market Reaction
The positive clinical data boosted VKTX stock, which was up 5.65% at $77.00 during the premarket session on Monday.
Conclusion
The data presented at ObesityWeek 2024 reinforces VK2735’s potential as a significant treatment option for obesity. Its ability to induce substantial weight loss, improve metabolic parameters, and demonstrate a favorable safety profile makes it a promising contender in the fight against this widespread health concern.
